Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

The Gamble Behind a Takeover of Kenvue, Maker of Tylenol

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears to think they’re manageable.

Andrew Ross Sorkin
Author: Andrew Ross Sorkin

Written by

Andrew Ross Sorkin

in

internal-storyline-no, Johnson & Johnson, Kenvue Inc, Kimberly-Clark Corporation, Liability for Products, Mergers, Acquisitions and Divestitures, Starboard Value LP, Stocks and Bonds, Tylenol (Drug)
←5 Things To Watch On Election Day 2025
Street Style Look of the Week: Fabric Layering→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube